{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:58:07Z","timestamp":1784649487586,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009388","name":"Jazan University","doi-asserted-by":"publisher","award":["296"],"award-info":[{"award-number":["296"]}],"id":[{"id":"10.13039\/100009388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00210-025-04574-1","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:39:38Z","timestamp":1756895978000},"page":"2577-2591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mapping the global research landscape of tirzepatide: a bibliometric analysis of trends, collaborations, and emerging themes in obesity and diabetes managements"],"prefix":"10.1007","volume":"399","author":[{"given":"Manal Mohamed Elhassan","family":"Taha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddig Ibrahim","family":"Abdelwahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Oraibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Madkhali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulhameed Albarraq","family":"Alhazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Jeraiby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh M.","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Farasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jobran M.","family":"Moshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar A.","family":"Khamjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Alshahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussam M.","family":"Shubaily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled A.","family":"Sahli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Qadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani","family":"Khardali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"4574_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.36740\/WLek\/202970","volume":"78","author":"A Alathary","year":"2025","unstructured":"Alathary A, Al-Isawi Z (2025) Tirzepatide therapy counters inflammatory and apoptotic responses induced by high-fat diet in rat liver. Wiad Lek 78:797\u2013805","journal-title":"Wiad Lek"},{"key":"4574_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111770","volume":"214","author":"A Alfakhri","year":"2024","unstructured":"Alfakhri A, Almadani O, Althunian T, Alrwisan A, Badreldin H, Albogami Y (2024) Treatment modification patterns of glucose-lowering agents in Saudi Arabia: a retrospective real-world data analysis. Diabetes Res Clin Pract 214:111770","journal-title":"Diabetes Res Clin Pract"},{"key":"4574_CR3","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1007\/s12325-023-02426-z","volume":"40","author":"HA Al-Omar","year":"2023","unstructured":"Al-Omar HA, Alshehri A, Abanumay A, Alabdulkarim H, Alrumaih A, Eldin MS, Alqahtani SA (2023) The impact of obesity in Saudi Arabia: healthcare resource use and costs associated with obesity-related complications. Adv Ther 40:1430\u20131443","journal-title":"Adv Ther"},{"key":"4574_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-025-00623-1","volume":"14","author":"I\u0391 Anastasiou","year":"2025","unstructured":"Anastasiou I\u0391, Argyrakopoulou G, Dalamaga M, Kokkinos A (2025) Dual and triple gut peptide agonists on the horizon for the treatment of type 2 diabetes and obesity. An overview of preclinical and clinical data. Curr Obes Rep 14:34","journal-title":"Curr Obes Rep"},{"key":"4574_CR5","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","volume":"11","author":"M Aria","year":"2017","unstructured":"Aria M, Cuccurullo C (2017) Bibliometrix: an R-tool for comprehensive science mapping analysis. J Informetr 11:959\u2013975","journal-title":"J Informetr"},{"key":"4574_CR6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416394","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP (2025) Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2416394","journal-title":"N Engl J Med"},{"key":"4574_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.16263","volume":"27","author":"M Bl\u00fcher","year":"2025","unstructured":"Bl\u00fcher M (2025) An overview of obesity-related complications: the epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes. Diabetes Obes Metab 27:3\u201319","journal-title":"Diabetes Obes Metab"},{"key":"4574_CR8","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1111\/dom.15680","volume":"26","author":"A Buckley","year":"2024","unstructured":"Buckley A, Suliman S, Allum M, Mohammed N, Lessan N, le Roux CW, Suliman M (2024) Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population. Diabetes Obes Metab 26:3381\u20133391","journal-title":"Diabetes Obes Metab"},{"key":"4574_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-5581-3-1","volume":"3","author":"JF Burnham","year":"2006","unstructured":"Burnham JF (2006) Scopus database: a review. Biomed Dig Libr 3:1\u20138","journal-title":"Biomed Dig Libr"},{"key":"4574_CR10","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1007\/s40618-024-02441-z","volume":"47","author":"I Caruso","year":"2024","unstructured":"Caruso I, Di Gioia L, Di Molfetta S, Caporusso M, Cignarelli A, Sorice GP, Laviola L, Giorgino F (2024) The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. J Endocrinol Invest 47:2671\u20132678","journal-title":"J Endocrinol Invest"},{"key":"4574_CR11","first-page":"1","volume":"1","author":"C Chen","year":"2014","unstructured":"Chen C (2014) The citespace manual. College of Comput Informs 1:1\u201384","journal-title":"College of Comput Informs"},{"key":"4574_CR12","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ (2021) Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 398:1811\u20131824","journal-title":"Lancet"},{"key":"4574_CR13","doi-asserted-by":"publisher","first-page":"S1513","DOI":"10.14309\/01.ajg.0001037848.29175.a2","volume":"119","author":"MA Espinosa","year":"2024","unstructured":"Espinosa MA, Fansa S, Anazco D, Ghusn W, Elif T, Cifuentes L, Alejandro C, Rivera R, Hurtado MD, Acosta A (2024) S2120 tirzepatide and MASLD: real-world outcomes in patients with overweight and obesity. Am J Gastroenterol 119:S1513\u2013S1514","journal-title":"Am J Gastroenterol"},{"key":"4574_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.998816","volume":"13","author":"R Guan","year":"2022","unstructured":"Guan R, Yang Q, Yang X, Du W, Li X, Ma G (2022) Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a bayesian network meta-analysis. Front Pharmacol 13:998816","journal-title":"Front Pharmacol"},{"key":"4574_CR15","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1111\/dom.16290","volume":"27","author":"ER Hankosky","year":"2025","unstructured":"Hankosky ER, Chinthammit C, Meeks A, Huang A, Ward JM, Mojdami D, Gibble TH (2025) Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: results from the Optum Market Clarity database. Diabetes Obes Metab 27:2810\u20132821","journal-title":"Diabetes Obes Metab"},{"key":"4574_CR16","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I (2025) Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med 392:958\u2013971","journal-title":"N Engl J Med"},{"key":"4574_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cegh.2024.101805","author":"A Khurana","year":"2024","unstructured":"Khurana A, Rabbani SA, El-Tanani M, Arora MK, Sharma S, Dubey H, Aljabali AA, Tambuwala MM (2024) Safety profile of tirzepatide: a real-world pharmacovigilance analysis of EudraVigilance database. Clin Epidemiol Global Health. https:\/\/doi.org\/10.1016\/j.cegh.2024.101805","journal-title":"Clin Epidemiol Global Health"},{"key":"4574_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101761","author":"Y Li","year":"2025","unstructured":"Li Y, Sun W, Liu H, Ruan XZ (2025) Tirzepatide, a dual GIP\/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A. Genes Dis. https:\/\/doi.org\/10.1016\/j.gendis.2025.101761","journal-title":"Genes Dis"},{"key":"4574_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s12020-020-02352-y","volume":"69","author":"X Lin","year":"2020","unstructured":"Lin X, Xu Y, Xu J, Pan X, Song X, Shan L, Zhao Y, Shan P-F (2020) Global burden of noncommunicable disease attributable to high body mass index in 195 countries and territories, 1990\u20132017. Endocrine 69:310\u2013320","journal-title":"Endocrine"},{"key":"4574_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110311","volume":"120","author":"Q Liu","year":"2023","unstructured":"Liu Q, Zhu J, Kong B, Shuai W, Huang H (2023) Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4\/NF-kB\/NLRP3 pathway. Int Immunopharmacol 120:110311","journal-title":"Int Immunopharmacol"},{"key":"4574_CR21","first-page":"441","volume":"31","author":"L Liu","year":"2025","unstructured":"Liu L, Cui J, Neidecker MV, Nahata MC (2025) Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: a short-term cost-effectiveness analysis in the United States. J Manag Care Spec Pharm 31:441\u2013450","journal-title":"J Manag Care Spec Pharm"},{"key":"4574_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, Yoneda M, Behling C, Cummings OW, Tang Y, Brouwers B, Robins DA, Nikooie A, Bunck MC, Haupt A, Sanyal AJ (2024) Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 391:299\u2013310","journal-title":"N Engl J Med"},{"key":"4574_CR23","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s12020-024-04013-w","volume":"87","author":"J Ma","year":"2025","unstructured":"Ma J, Liu Y, Hu J, Liu X, Xia Y, Xia W, Shen Z, Kong X, Wu X, Mao L, Li Q (2025) Tirzepatide administration improves cognitive impairment in HFD mice by regulating the SIRT3-NLRP3 axis. Endocrine 87:486\u2013497","journal-title":"Endocrine"},{"key":"4574_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1017\/S0266462312000086","volume":"28","author":"A Morrison","year":"2012","unstructured":"Morrison A, Polisena J, Husereau D, Moulton K, Clark M, Fiander M, Mierzwinski-Urban M, Clifford T, Hutton B, Rabb D (2012) The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care 28:138\u2013144","journal-title":"Int J Technol Assess Health Care"},{"key":"4574_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","volume":"21","author":"MA Nauck","year":"2022","unstructured":"Nauck MA, D\u2019Alessio DA (2022) Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol 21:169","journal-title":"Cardiovasc Diabetol"},{"key":"4574_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ (2018) Incretin hormones: their role in health and disease. Diabetes Obes Metab 20:5\u201321","journal-title":"Diabetes Obes Metab"},{"key":"4574_CR27","volume":"17","author":"H Okuma","year":"2025","unstructured":"Okuma H (2025) Effects of tirzepatide on patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a retrospective cohort study. Cureus 17:e83712","journal-title":"Cureus"},{"key":"4574_CR28","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s13300-025-01728-5","volume":"16","author":"B Osumili","year":"2025","unstructured":"Osumili B, Sapin H, Yang Z, Ranta K, Paik JS, Bl\u00fcher M (2025) Efficacy and safety of tirzepatide compared with GLP-1 RAs in patients with type 2 diabetes treated with basal insulin: a network meta-analysis. Diabetes Ther 16:1279\u20131311","journal-title":"Diabetes Ther"},{"key":"4574_CR29","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/oby.24002","volume":"32","author":"XH Pan","year":"2024","unstructured":"Pan XH, Tan B, Chin YH, Lee ECZ, Kong G, Chong B, Kueh M, Khoo CM, Mehta A, Majety P, Grandhi GR, Dimitriadis GK, Foo R, Chew NWS, Le Roux CW, Mamas MA, Chan MY (2024) Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis. Obesity (Silver Spring) 32:840\u2013856","journal-title":"Obesity (Silver Spring)"},{"key":"4574_CR30","unstructured":"Pingault N, Caron P, Kalafatic C, Allahoury A, Fresco LO, Kennedy E, Khan M, Kliksberg B, Mei F, Murphy S (2017) Nutrition and food systems. A report by the High Level Panel of Experts on Food Security and Nutrition of the Committee on World Food Security. pp 47\u201360. https:\/\/shorturl.at\/o3ACO"},{"key":"4574_CR31","doi-asserted-by":"publisher","DOI":"10.51757\/IJEHS.5.2024.718434","author":"Prince-Edward OR","year":"2024","unstructured":"Prince-Edward OR (2024) Obesity epidemiology in Nigeria: overview. International Journal of Epidemiology and Health Sciences. https:\/\/doi.org\/10.51757\/IJEHS.5.2024.718434","journal-title":"International Journal of Epidemiology and Health Sciences"},{"key":"4574_CR32","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/17446651.2024.2395540","volume":"19","author":"SA Rabbani","year":"2024","unstructured":"Rabbani SA, El-Tanani M, Matalka II, Rangraze IR, Aljabali AA, Khan MA, Tambuwala MM (2024) Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management. Expert Rev Endocrinol Metab 19:487\u2013505","journal-title":"Expert Rev Endocrinol Metab"},{"key":"4574_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16466","author":"M Tang","year":"2025","unstructured":"Tang M, Shi L, Guan D, Winberg D, Tang T, Shao H, Fonseca V (2025) Long-term cost-effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity. Diabetes Obes Metab. https:\/\/doi.org\/10.1111\/dom.16466","journal-title":"Diabetes Obes Metab"},{"key":"4574_CR34","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12902-024-01805-z","volume":"24","author":"Y Teng","year":"2024","unstructured":"Teng Y, Fan X, Yu R, Yang X (2024) Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis. BMC Endocr Disord 24:278","journal-title":"BMC Endocr Disord"},{"key":"4574_CR35","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"N Van Eck","year":"2010","unstructured":"Van Eck N, Waltman L (2010) Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84:523\u2013538","journal-title":"Scientometrics"},{"key":"4574_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/apt.18042","volume":"60","author":"R Vuppalanchi","year":"2024","unstructured":"Vuppalanchi R, Loomba R, Sanyal AJ, Nikooie A, Tang Y, Robins DA, Brouwers B, Hartman ML (2024) Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures. Aliment Pharmacol Ther 60:17\u201332","journal-title":"Aliment Pharmacol Ther"},{"key":"4574_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113499","volume":"143","author":"Y Xia","year":"2024","unstructured":"Xia Y, Jin J, Sun Y, Kong X, Shen Z, Yan R, Huang R, Liu X, Xia W, Ma J, Zhu X, Li Q, Ma J (2024) Tirzepatide\u2019s role in targeting adipose tissue macrophages to reduce obesity-related inflammation and improve insulin resistance. Int Immunopharmacol 143:113499","journal-title":"Int Immunopharmacol"},{"key":"4574_CR38","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s11010-024-05066-1","volume":"480","author":"Y Yang","year":"2025","unstructured":"Yang Y, Wang Y, Zhou Y, Deng J, Wu L (2025) Tirzepatide alleviates oxidative stress and inflammation in diabetic nephropathy via IL-17 signaling pathway. Mol Cell Biochem 480:1241\u20131254","journal-title":"Mol Cell Biochem"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04574-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04574-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04574-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T01:08:50Z","timestamp":1771549730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04574-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4574"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04574-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}